Literature DB >> 25963904

The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.

C J Bailey1.   

Abstract

The escalating global epidemic of type 2 diabetes mellitus has focused attention on the devastating consequences of protracted hyperglycemia. Early and effective intervention to control blood glucose is a fundamental principle of treatment guidelines, requiring assiduous use of current therapies. However, many patients do not achieve or maintain glycemic targets, emphasizing the need for further therapies. This narrative review assesses the available medicinal options to address hyperglycemia and the opportunities to develop novel agents.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25963904     DOI： 10.1002/cpt.144

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  24 in total

1.  Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.

Authors:  Caslin A Gilroy; Stefan Roberts; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2018-03-15       Impact factor: 9.776

Review 2.  Controlled release of biologics for the treatment of type 2 diabetes.

Authors:  Caslin A Gilroy; Kelli M Luginbuhl; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-12-02       Impact factor: 9.776

Review 3.  Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery.

Authors:  Kaixin Zhou; Helle Krogh Pedersen; Adem Y Dawed; Ewan R Pearson
Journal:  Nat Rev Endocrinol       Date:  2016-04-11       Impact factor: 43.330

Review 4.  Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.

Authors:  Abd A Tahrani; Anthony H Barnett; Clifford J Bailey
Journal:  Nat Rev Endocrinol       Date:  2016-06-24       Impact factor: 43.330

5.  Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study.

Authors:  Manel Mata-Cases; Josep Franch-Nadal; Jordi Real; Dídac Mauricio
Journal:  BMJ Open       Date:  2016-10-05       Impact factor: 2.692

Review 6.  Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management.

Authors:  Arun Chaudhury; Chitharanjan Duvoor; Vijaya Sena Reddy Dendi; Shashank Kraleti; Aditya Chada; Rahul Ravilla; Asween Marco; Nawal Singh Shekhawat; Maria Theresa Montales; Kevin Kuriakose; Appalanaidu Sasapu; Alexandria Beebe; Naveen Patil; Chaitanya K Musham; Govinda Prasad Lohani; Wasique Mirza
Journal:  Front Endocrinol (Lausanne)       Date:  2017-01-24       Impact factor: 5.555

7.  Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy.

Authors:  Wei Chen; Rui Tian; Can Xu; Bryant C Yung; Guohao Wang; Yijing Liu; Qianqian Ni; Fuwu Zhang; Zijian Zhou; Jingjing Wang; Gang Niu; Ying Ma; Liwu Fu; Xiaoyuan Chen
Journal:  Nat Commun       Date:  2017-11-24       Impact factor: 14.919

Review 8.  Biology of Beige Adipocyte and Possible Therapy for Type 2 Diabetes and Obesity.

Authors:  Fernando Lizcano; Diana Vargas
Journal:  Int J Endocrinol       Date:  2016-07-26       Impact factor: 3.257

9.  Prevalence and treatment of diabetes mellitus and hypertension among older adults with intellectual disability in comparison with the general population.

Authors:  Anna Axmon; Gerd Ahlström; Peter Höglund
Journal:  BMC Geriatr       Date:  2017-11-23       Impact factor: 3.921

10.  Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.

Authors:  Kaixin Zhou; Sook Wah Yee; Eric L Seiser; Nienke van Leeuwen; Roger Tavendale; Amanda J Bennett; Christopher J Groves; Ruth L Coleman; Amber A van der Heijden; Joline W Beulens; Catherine E de Keyser; Linda Zaharenko; Daniel M Rotroff; Mattijs Out; Kathleen A Jablonski; Ling Chen; Martin Javorský; Jozef Židzik; Albert M Levin; L Keoki Williams; Tanja Dujic; Sabina Semiz; Michiaki Kubo; Huan-Chieh Chien; Shiro Maeda; John S Witte; Longyang Wu; Ivan Tkáč; Adriaan Kooy; Ron H N van Schaik; Coen D A Stehouwer; Lisa Logie; Calum Sutherland; Janis Klovins; Valdis Pirags; Albert Hofman; Bruno H Stricker; Alison A Motsinger-Reif; Michael J Wagner; Federico Innocenti; Leen M 't Hart; Rury R Holman; Mark I McCarthy; Monique M Hedderson; Colin N A Palmer; Jose C Florez; Kathleen M Giacomini; Ewan R Pearson
Journal:  Nat Genet       Date:  2016-08-08       Impact factor: 38.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.